目的 探究小兒抗癇膠囊聯(lián)合丙戊酸鈉緩釋片（I）治療兒童原發(fā)性全身強(qiáng)直–陣攣發(fā)作型癲癇的臨床療效及其對(duì)膠質(zhì)纖維酸性蛋白（GFAP）、S100β蛋白水平的影響。方法 選取2018年2月—2020年2月在開封市兒童醫(yī)院就診的120例原發(fā)性全身強(qiáng)直–陣攣發(fā)作型癲癇患兒為研究對(duì)象，按照隨機(jī)數(shù)字表法將全部患兒分為對(duì)照組和治療組，每組各60例。對(duì)照組患兒口服丙戊酸鈉緩釋片（I），30 mg/(kg∙d)。治療組在對(duì)照組用藥基礎(chǔ)上口服小兒抗癇膠囊，5粒/次，3次/d。2個(gè)月為1個(gè)療程，兩組患兒均連續(xù)治療3個(gè)療程。觀察兩組患兒的臨床療效，并比較兩組患兒治療前后腦電圖特征、癲癇發(fā)作持續(xù)時(shí)間、癲癇發(fā)作頻率、GFAP、S100β蛋白水平情況。結(jié)果 治療后，治療組總有效率（93.33%）明顯高于對(duì)照組（80.00%）（P<0.05）。治療后，兩組患兒θ功率均較治療前增加（P<0.05），且治療組θ功率顯著高于對(duì)照組（P<0.05）。治療后，兩組患兒癲癇發(fā)作持續(xù)時(shí)間、發(fā)作頻率均明顯降低（P<0.05）；且與對(duì)照組比較，治療組癲癇發(fā)作持續(xù)時(shí)間、發(fā)作頻率明顯降低（P<0.05）。治療后，兩組GFAP、S100β水平均降低（P<0.05），且治療組GFAP、S100β水平較對(duì)照組低（P<0.05）。結(jié)論 小兒抗癇膠囊聯(lián)合丙戊酸鈉緩釋片（I）治療兒童原發(fā)性全身強(qiáng)直–陣攣發(fā)作型癲癇療效顯著，能夠有效改善患兒臨床癥狀、腦電圖特征、θ功率和GFAP、S100β水平，且不會(huì)增加不良反應(yīng)。

Objective To investigate the clinical effect of Xiao’er Kangxian Capsules combined with Sodium Valproate Sustained-release Tablets (I) in treatment of primary systemic tonic-clonic seizure epilepsy in children and its effect on the levels of GFAP and S-100β.Methods Children (120 cases) with primary systemic tonic-clonic seizure epilepsy in Kaifeng Children’s Hospital from February 2018 to February 2020 were randomly divided into control and treatment groups, and each group had 60 cases. Children in the control group were po administered with Sodium Valproate Sustained-release Tablets (I), 30 mg/(kg∙d). Children in the treatment group were po administered with Xiao’er Kangxian Capsules on the basis of the control group, 5 grains/time, three times daily. A course had 2 months, and children in two groups were treated for 3 courses. After treatment, the clinical efficacies were evaluated, and the EEG characteristics, the duration and frequency of seizure, the levels of serum GFAP and S100β in two groups were compared.Results After treatment, the total effective rate of the treatment group (93.33%) was significantly higher than that of the control group (80.00%) (P<0.05). After treatment, the θ power of two groups were increased compared with that before treatment (P<0.05), and the θ power of the treatment group was significantly higher than that of the control group (P<0.05). After treatment, the duration and frequency of seizures in two groups were significantly decreased (P<0.05), and the duration and frequency of seizures in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of GFAP and S100β in two groups were decreased (P<0.05), and the levels of GFAP and S100β in the treatment group were lower than those in the control group (P<0.05).Conclusion Xiao’er Kangxian Capsules combined with Sodium Valproate Sustained-release Tablets (I) has a significant effect on children with primary generalized tonic-clonic seizure epilepsy, can effectively improve the EEG, θ power, GFAP and S100β levels and clinical symptoms, with less adverse reactions.

R985

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（2018020531）